Andere Kunden interessierten sich auch für
![New approach in treatment of brain injury]( "New approach in treatment of brain injury")
New approach in treatment of brain injury26,99 €![The transcription factor CcpN from Bacillus subtilis]( "The transcription factor CcpN from Bacillus subtilis")
The transcription factor CcpN from Bacillus subtilis39,99 €![Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2]( "Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2")
Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2148,99 €![Complement and antibodies in cancer]( "Complement and antibodies in cancer")
Complement and antibodies in cancer56,99 €![Complement Receptor Type 1 Expression and Genotype Relationships]( "Complement Receptor Type 1 Expression and Genotype Relationships")
Complement Receptor Type 1 Expression and Genotype Relationships26,99 €![Biochemical Diagnosis and Protection of Cardiac Ischemia]( "Biochemical Diagnosis and Protection of Cardiac Ischemia")
Biochemical Diagnosis and Protection of Cardiac Ischemia62,99 €![The Role of Neurotransmitters in Brain Injury]( "The Role of Neurotransmitters in Brain Injury")
The Role of Neurotransmitters in Brain Injury112,99 €
Complement factor H (CFH) is the major regulator of the alternative pathway of complement and mutations and genetic polymorphisms in the CFH gene predispose to severe human diseases. In this study a novel method of purifying CFH from pooled human plasma is demonstrated. Furthermore, the question is addressed of purified human CFH being successful option as therapeutic complement inhibitor in a preclinical model of human disease with implication of complement activation in its patho-mechanism. Intestinal ischemia reperfusion injury was induced in rats. Significant local complement deposition and local tissue injury on the ileal mucosa was determined providing a rationale to administer human CFH as therapeutic and subsequently test the hypothesis that intravenous application of human CFH would protect rats from clinical manifestations of intestinal IRI. The mechanism of action of therapeutic CFH in a rat model of a clinically relevant human disorder is lastly demonstrated and future prospects on CFH as therapeutic complement inhibitor are discussed in detail. This book focuses on scientists, post-docs and pre-doctoral students working in the field of translational complement biology.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.